Overcoming Cancer Resistance to Platinum Drugs by Inhibiting Cholesterol Metabolism
Angewandte Chemie International Edition · 16.10.2023 · 62 (42)
DOI: 10.1002/anie.202309043 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, online erschienen am 08.09.2023. Verfasst von Ying Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, 210023, P. R. China. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Cholesterol, Antineoplastic Agents, Organoplatinum Compounds. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 64 Literaturangaben. Gefördert von: Natural Science Foundation of Xiamen City, National Natural Science Foundation of China, Natural Science Foundation of Xiamen Municipality.
Abstract (Originalsprache)
Drug resistance is a serious challenge for platinum anticancer drugs. Platinum complexes may get over the drug resistance via a distinct mechanism of action. Cholesterol is a key factor contributing to the drug resistance. Inhibiting cellular cholesterol synthesis and uptake provides an alternative strategy for cancer treatment. Platinum(IV) complexes FP and DFP with fenofibric acid as axial ligand(s) were designed to combat the drug resistance through regulating cholesterol metabolism besides damaging DNA. In addition to producing reactive oxygen species and active platinum(II) species to damage DNA, FP and DFP inhibited cellular cholesterol accumulation, promoted cholesterol efflux, upregulated peroxisome proliferator‐activated receptor alpha (PPARα), induced caspase‐1 activation and gasdermin D (GSDMD) cleavage, thus leading to both apoptosis and pyroptosis in cancer cells. The reduction of cholesterol significantly relieved the drug resistance of cancer cells. The double‐acting mechanism gave the complexes strong anticancer activity in vitro and in vivo, particularly against cisplatin‐resistant cancer cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, 210023, P. R. China.
- State Key Laboratory of Coordination Chemistry, School of Chemistry and Chemical Engineering, Nanjing University, Nanjing, 210023, P. R. China.
ORCID-Profile: Xiaoyong Wang
Förderung
- Natural Science Foundation of Xiamen City
- National Natural Science Foundation of China
- Natural Science Foundation of Xiamen Municipality
Zitieren
APA
Wang, Y., Cai, L., Li, H., Chen, H., Yang, T., Tan, Y., Guo, Z., & Wang, X. (2023). Overcoming Cancer Resistance to Platinum Drugs by Inhibiting Cholesterol Metabolism. Angewandte Chemie International Edition, 62(42). https://doi.org/10.1002/anie.202309043
Vancouver
Wang Y, Cai L, Li H, Chen H, Yang T, Tan Y, et al. Overcoming Cancer Resistance to Platinum Drugs by Inhibiting Cholesterol Metabolism. Angewandte Chemie International Edition. 2023;62(42). doi:10.1002/anie.202309043
BibTeX
@article{Wang2023,
author = {Wang, Ying and Cai, Linxiang and Li, Hui and Chen, Hanhua and Yang, Tao and Tan, Yehong and Guo, Zijian and Wang, Xiaoyong},
title = {Overcoming Cancer Resistance to Platinum Drugs by Inhibiting Cholesterol Metabolism},
journal = {Angewandte Chemie International Edition},
year = {2023},
volume = {62},
number = {42},
doi = {10.1002/anie.202309043}
}
EUVIMED